Telaprevir
From Proteopedia
(Difference between revisions)
| Line 1: | Line 1: | ||
<StructureSection load='3sv6' size='340' side='right' caption='Crystal structure of NS3/4A protease in complex with Telaprevir ([[3sv6]])' scene='96/969645/Cv/1'> | <StructureSection load='3sv6' size='340' side='right' caption='Crystal structure of NS3/4A protease in complex with Telaprevir ([[3sv6]])' scene='96/969645/Cv/1'> | ||
| - | Telaprevir (VX-950), marketed under the brand names Incivek and Incivo, is a pharmaceutical drug for the treatment of hepatitis C co-developed by Vertex Pharmaceuticals and Johnson & Johnson. It is a member of a class of antiviral drugs known as protease inhibitors. Specifically, telaprevir inhibits the hepatitis C viral enzyme NS3/4A serine protease. See also [https://en.wikipedia.org/wiki/Telaprevir]. | + | Telaprevir (VX-950), marketed under the brand names Incivek and Incivo, is a pharmaceutical drug for the treatment of hepatitis C co-developed by Vertex Pharmaceuticals and Johnson & Johnson. It is a member of a class of antiviral drugs known as protease inhibitors. Specifically, telaprevir inhibits the hepatitis C viral enzyme NS3/4A [[serine protease]]. See also [https://en.wikipedia.org/wiki/Telaprevir]. |
<scene name='96/969645/Overall/1'>Crystal structure of NS3/4A protease in complex with Telaprevir</scene> ([[3sv6]]). | <scene name='96/969645/Overall/1'>Crystal structure of NS3/4A protease in complex with Telaprevir</scene> ([[3sv6]]). | ||
Current revision
| |||||||||||
